QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Northwest Biotherapeutics, Inc. (NWBO) Announces Increase in Clinical Trial Sites for Its Immunotherapy Product DCVax® 0 comments
    Aug 4, 2011 6:27 PM | about stocks: NWBO

    Northwest Biotherapeutics, a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer, today announced that it is on target to fulfill its prior projection that it will have fifteen clinical trial sites open and active in Q3 of this year for its DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.

    The Company now has twelve sites where there is an ongoing clinical trial of DCVax® immune therapy, including UCLA, New York University, Baylor Research Institute and Henry Ford Hospital. The Company’s cancer therapies have demonstrated in clinical trials to significantly extend both time to recurrence and survival, with no debilitating side effects when compared with current therapies.

    The positive data from the Company’s prior clinical trials of DCVax®, where the median survival rate was 3 years versus only 14.6 months with standard of care today and patients did not have a recurrence of their tumor for approximately 2 years without toxic-side effects as compared with normal care tumor recurrence in just 7 months, has had the Company receiving positive interest from both patients and physicians from around the country.

    “We are excited to be able to offer patients access to this promising new approach to treating brain cancer. DCVax holds great promise to improve outcomes by stimulating the patient’s own anti-tumor immune response while not disrupting their current standard of care treatments. Another advantage is a trial design that allows all patients to have the opportunity to receive the vaccine during the course of the study. It is refreshing to see a company design a trial which puts the patient’s interests first,” said Dr. Greg Foltz in a press release today.

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net


    Stocks: NWBO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.